Ivermectin;Ivermectine

Annales de Dermatologie et de Venereologie

Volumn 131, Issue 6-7 I, 2004, Pages 561-570

  Develoux, M ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; DERMATOLOGICAL AGENT; DIETHYLCARBAMAZINE; ION CHANNEL; IVERMECTIN; MACROLIDE; TIABENDAZOLE;

ASCARIASIS; BRUGIA MALAYI; CELL MEMBRANE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STRUCTURE; EYE DISEASE; FILARIASIS; HUMAN; LARVA MIGRANS; LOA LOA; MICROFILARIASIS; ONCHOCERCA VOLVULUS; PARASITE TRANSMISSION; PEDICULUS; REVIEW; SCABIES; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TREATMENT INDICATION; WUCHERERIA BANCROFTI;

EID: 4143114690     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(04)93668-x     Document Type: Review

References (61)

1. Goa KL, McTavish D, Clissod SP. Ivermectin: a review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs 1991;42:640-58.
2. Ette IE, Wilkinson OAT, Achumba JI. Ivermectin: a long-acting microfilaricidial agent. DICP Ann Pharmacother 1990;24:426-3.
3. Boussinesq M, Hougard JM. La lutte contre l'onchocercose en Afrique: aspects actuels. Med Trop 1998;58:285-96.
4. Ottensen EA, Campbell WC. Ivermectin in human medicine. J Antimicrob Chemother 1994;34:195-203.
5. Datry A, Thellier M, Alfa-Cisse O, Danis M, Caumes E. L'ivermectine, un antiparasitaire à large spectre. Presse med 2002;31:605-9.
6. Elgart GW, Meinking TL. Ivermectin. Dermatol Clin 2003;21:277-82.
7. Soboslay PT, Dreweck CM, Hoffman WH, Lüder CGK, Heuschkel C, Gorgen H et al. Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment. Clin Exp Immunol 1992;89:407-13.
8. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt et al. Safety, tolerability and pharmacokinetics of escalationg high doses of ivermectin in healthy adult subjets. J Clin Pharmacol 2002;42:1122-33.
9. Fink DW, Poras AG. Pharmacocinetics of ivermectin in animals and man. In Campbell WC (Ed) Ivermectin and abamectin. Springer-Verlag, New-York, 1989:113-20.
10. Edwards G, Dingsdale A, Helsby N, Orne ML'E, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol 1988;35:681-4.
11. Klotz U, Ogbuokiri JE, Onkonkwo PO. Ivermectin binds avidity to plasma proteins. Eur J Clin Pharmacol 1990;39:607-8.
12. Haas N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch Dermatol 2002;138:1618-9.
13. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MMA, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin pharmacol 1996;50:407-10.
14. Aziz MA, Diallo S, Diop IM, Lariviere M, Porta M. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 1982;2:171-3.
15. Greene BM, Taylor HR, Cupp EW, Murphy RP, Withe AT, Aziz MA et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985;313:133-8.
16. Prod'hon J, Boussinesq M, Fobi G, Prud'hom JM, Enyong P, Lafleur C, Quillévéré D. Lutte contre l'onchocercose par ivermectine: résultats d'une campagne de masse au Nord-Cameroun. Bull OMS 1991;69:443-50.
17. Mabey D, Whitworth JA, Eckstein M, Gilbert C, Maude G, Downham M. The effects of multiple doses of ivermectin on ocular onchocerciasis. Ophtalmology 1996;103:1001-8.
18. Ogbuagu KF, Eneanya CI. A multi-centre study of the effect of mectizan treatment on onchocercal skin disease: clinical findings. Ann Trop Med Parasitol 1998;92 (Suppl 1): S1139-45.
19. Al Qubati Y, Reynouard F, Kumar F, Gaxotte P, Richard-Lenoble D. Onchodermatite (Sowda) chez des patients du Yémen. Evolution clinique et histologique après traitement par ivermectine. Cahiers Santé 1997;7: 391-5.
20. Kumaraswami V, Ottesen EA, Vijayasekaran V, Uma Devi S, Swaminthan M, Aziz MA et al. Ivermectin for the treatment of Wuchereria bancrofti filariasis. JAMA 1988;259:3150-3.
21. Ottesen EA, Vijayasekaran V, Kumaraswami V, Perumal Pillai SV, Sadanadam A, Frederick S et al. A control trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 1990;322:1113-7.
22. Bockarie J, Alexander NDE, Hyun P, Dimber Z, Bockarie F, Ibam E et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 1998;351:162-8.
23. Bockarie MJ, Tish DJ, Kastens W, Alexander NDE, Dimber Z, Bockarie F et al. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 2002;347:1841-8.
24. Richard-Lenoble D, Kombila M, Rupp E, Pappayliou E, Gaxotte P, Nguiri C, Aziz M. Ivermectin in loasis and concomitant O volvulus and M perstans infections. Am J Trop Med Hyg 1988;39:480-3.
25. Duong TH, Kombila M, Ferrer A, Bureau P, Gaxotte P, Richard-Lenoble D. Reduced Loa loa microfilaria count ten to twelve months after a single dose of ivermectin. Trans R Soc Trop Med Hyg 1997;91:592-3.
26. Fisher P, Tukesiga E, Büttner DW. Long-term suppression of Mansonella streptocerca microfilariae after treatment with ivermectin. J Inf Dis 1999;180:1403-5.
27. Gardon J, Kamgno J, Gardon-Wendel N, Demanga-Ngange, Duke BOL, Boussinesq M. Efficacy of repeated doses of ivermectin against Mansonella perstans. Trans R Soc Trop Med Hyg 2002;96:325-6.
28. González AA, Dave D, Chadee DD, Rawlins SC. Single dose of ivermectin to control mansonellosis in Trinidad: a four years follow-up study. Trans R Soc Trop Med Hyg 1998;92:570-1.
29. Naquira C, Jimenez G, Guerra JG, Bernal R, Nalin DR, Neu D, Aziz M. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989;40:304-9.
30. Gann PH, Neva FA, Gam AA. A randomized trial of single and two-dose overmectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;164:1076-9.
31. Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, Ameir JS, Hatz C. A comparative trial of a single-dose ivermectin versus three days of albendazole for the treatment of Strongyloïdes stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996;55:477-81.
32. Caumes E, Datry A, Mayorga R, Gaxotte P, Danis M, Gentilini M. Efficacy of ivermectin in the therapy of larva currens. Arch Dermatol 1994;130:932.
33. Louis JF, De Quincenet G, Louis JP. Intérêt de l'ivermectine en prise unique dans le traitement du syndrome de larva migrans cutanée. Presse med 1992;21:1443.
34. Caumes E, Datry A, Paris L, Danis M, Gentilini M, Gaxotte P. Efficacy of ivermectin in the therapy of cutaneous larva migrans. Arch Dermatol 1992;128:994-5.
35. Bouchaud O, Schiemann R, Ralaimzava P, Longuet C, Ruggieri C, Coulaud JP. Cutaneous larva migrans in 60 travelers: epidemiological data and study of the efficacy of ivermectin. Clin Infect Dis 2000:31:493-8.
36. Caumes E, Carriére J, Datry A, Danis M, Gentilini M. A randomized trial of ivermectin versus albendazole in the treatment of cutaneous larva migrans. Am J Trop Med Hyg 1993;49:641-4.
37. Nontasut P, Bussaratid V, Chullawichit S, Charoensook N, Visetuk K. Comparison of ivermectin and albendazole treatment for gnathostomiasis. Southeast Asian J Trop Med Public Health 2000;31:374-7.
38. Macotela-Ruiz E, Peña-Gonzalez G. Tratamiento de la escabiasis con ivermectina por via oral. Gaseta Med de Mexico 1993;129:201-5.
39. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. N Engl J Med 1995;333:26-30.
40. Dourmishev A, Serafimova D, Dourmishev L. Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol 1998;11:247-51.
41. Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, Martin PMV. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol 1993;44:331-2.
42. Chouela EN, Abeldaño AM, Pellerano G, La Forgia M, Papale RM, Garsd A et al. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol 1999;135:651-5.
43. Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000;42:236-40.
44. Alberici F, Pagani I, Ratti G, Viale P. Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies. Br J Dermatol 2000;142:969-72.
45. Huffmam SE, Currie BJ. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis 1998;2:152-4.
46. Marty P, Gari-Toussaint M, Le Fichoux Y, Gaxotte P. Efficacy of ivermectin in the treatment of an epidemic of Sarcoptes scabiei. Ann Trop Med Parasitol 1994;88:453.
47. Dannaoui E, Kiazand A, Piens MA, Picot S. Use of ivermectin for the management of scabies in a nursing home. Eur J Dermatol 1999;9:443-5.
48. Leppard B, Naburi AE. The use of ivermectin in controlling an outbreak of scabies in a prison. Br J Dermatol 2000;143:520-1.
49. Glaziou P, Nyguyen LN, Moulia-Pelat JP, Cartel JL, Martin PMV. Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Trop Med Parasitol 1994;45:253-4.
50. Aquilina C, Viraben R, Sire S. Ivermectin-responsive Demodex infestation during human immunodeficiency virus infection. A case report and literature review. Dermatology 2002;205:394-7.
51. Burkhart CN, Burkhart CG. Oral ivermectin therapy for phthiriasis palpebrum. Arch Dermatol 2000;118:134-5.
52. Youssef MYM, Sadaka HAH, Eissa MM, El-Ariny AF. Topical application of ivermectin for human ectoparasites. Am J Trop Med Hyg 1995;53:652-3.
53. Victoria J, Trujillo R. Topical ivermectin: a new successful treatment for scabies. Pediatr Dermatol 2001;18:63-5.
54. Victoria J, Trujillo R, Barreto M. Myiasis: a successful treatment with topical ivermectin. Int J Dermatol 1999;38:142-4.
55. De Sole G, Remme, Awadzi K, Accorsi S, Alley ES, Ba O et al. Adverse reactions after Large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull WHO 1989;67:707-19.
56. Davidson RN, Godfrey-Fausset P, Bryceson ADM. Adverse reactions in expatriates treated with ivermectin. Lancet 1990;336:1005.
57. Boussinesq M, Gardon J. Challenges for the future: loasis. Ann Trop Med Parasitol 1998;92:S147-51.
58. Ducorps M, Gardon-Wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J et al. Effets secondaires du traitement de la loase hypermicrofilarémique par l'ivermectine. Bull Soc Path Ex 1995;88:105-12.
59. Cruel T, Arborio M, Schill H, Neveux Y, Nelec G, Chevalier B et al. Effets secondaires du traitement de la filariose à Loa loa. A propos d'un cas de réaction adverse à la prise d'ivermectine. Bull Soc Path Ex 1997;90:179-81.
60. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997;349:1144-45.
61. Pacque M, Muñoz B, Poetschke G, Foose J, Greene B, Taylor H. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 1990;336:1486-9.